Featured Topics

Key Issues

Toxicology Forum meetings result in productive discussions of highly controversial subjects that are of great importance to industry and government. This kind of leadership promotes change in the direction of toxicological research and permits debate on the public policy aspects of regulatory reform.  A vital part of all Toxicology Forum meetings is a session on emerging issues, recent scientific findings, or decisions of governments. These are an unparalleled source of up-to-date information.

Winter 2010

 

  • Keynote Address: Margaret Hamburg, Commissioner FDA
  • Phthalates and Cumulative Risk Assessment
  • Food Allergens: Thresholds for Adverse Reaction?
  • Biomonitoring: Health Risk Assessment Lags Behind Analytical Identification –a Benzene Case Study
  • Toxicology Testing in the 21st
  • Century: Applications and Opportunities in the Pharmaceutical Industry
  • New Diabetic Class of Drugs: Relevance of Rodent C-Cell Tumors Seen with Glucagon-like Peptide 1 (GLP-1)
  • Vetting the GRAS Process: Its History, Uses, and Future

Summer 2010

 

  • Nanoscale Materials: Exposures and Minimum Study Criteria for Protocols andPublications
  • Results and Regulatory Recommendations from Acrylamide Studies
  • Metabolism, Pharmacokinetics and Bioavailability of Bisphenol A
  • Nonclinical Assessment of Drug-Drug Interactions (DDI): Predictability of Effects in Patients
  • Preclinical Assessment of Neuropharmacological Effects: Bridging the Translational Divide
  • The Relevance of Rodent Tumor Mode of Action to Human Risk Assessment
  • Toxicology Testing in the 21st Century: Is This The Right Course for Better,Quicker Regulatory Decisions?

Europe 2010

 

  • Keynote Address: Corrado Galli, University of Milan
  • Is There a Need for a Second Rodent Species in Carcinogenicity Testing?
  • Assessing Risk From Short or Intermittent Exposure to Carcinogens
  • Safety of Synthetic Colors: Implications for the European Food Industry
  • Safety Assessment of Naturals
  • Basic Concepts of Drug-Receptor Interaction and the Human Relevance of Bisphenol A Toxicity